Launch Date for New Anesthetic Announced by Jurox

KANSAS CITY, Mo., Kansas City Animal Health Corridor, (August 11, 2014) – Jurox Animal Health announces the release date of their unique anesthetic Alfaxan® (alfaxalone 10 mg/mL), an intravenous injectable anesthetic for use in cats and dogs.  Alfaxan® is indicated for the induction and maintenance of anesthesia and for induction of anesthesia followed by maintenance with an inhalant anesthetic. Providing a repeatable, reliable alternative to current companion animal anesthetic protocols, Alfaxan® will be available to US veterinary practitioners on the 25th of August, 2014.  

Now available in 20 countries, Alfaxan® is the leading choice induction drug in Australia. An independent study commissioned by Jurox reported Australian veterinarians to rely on Alfaxan® for induction as often as 74% of the time in cats and 52% in dogs1.

"We are pleased to finally be in a position to bring our innovative product to the world's largest market. Since beginning this process (of registration) we have had countless inquiries as to why it has not been available to US veterinarians" commented Chief Executive of Jurox Inc., JJ O'Brien.

Supported by a team of 32, of which will include six veterinarians, Jurox will be partnering with six veterinary distributors to ensure national coverage. Product will be available through Henry Schein Animal Health, MWI, Patterson, NEVSCo, Midwest Veterinary Supply and Victor Medical.

For further information visit www.alfaxan.com or call toll free (844) ALFAXAN.

About Jurox

Jurox is an established family owned veterinary pharmaceutical company that manufactures and markets in excess of 120 proprietary animal health products in over 20 countries. With global headquarters in the Hunter Valley Australia, Jurox maintains commercial operations in New Zealand, United Kingdom and has recently established their U.S. headquarters in Kansas City, Missouri.

Jurox invests 15% of sales in research and development, much of which is carried out on the group's own research stations. The Company is GMP certified under MRA, US FDA inspected and NATA recognized for compliance with the OECD Principles of Good Laboratory Practice and ISO17025 Laboratory Accredited.

Jurox's mission is to deliver uncompromised quality driven by innovation, adding value for customers willing to work with a long-term partner committed to supporting their business' needs. Jurox aims to provide veterinarians, pet owners and livestock producers with innovative and practical solutions to improve the well-being and sustainability of Animal Health.

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…